transfer factor

Immune System and Immune System and Transfer FactorTransfer Factor

Immune SystemImmune SystemThe health of the The health of the body is body is dependent on the dependent on the immune system's immune system's ability to ability to recognize and recognize and then react and then react and remember germs remember germs and cancers.and cancers.

Major Lines of Immune DefenseMajor Lines of Immune Defense

Innate ImmunityInnate Immunity Passive ActivePassive Active Skin Inflammatory CellsSkin Inflammatory Cells Mucus Natural Killer CellsMucus Natural Killer Cells Stomach Acid Phagocytic CellsStomach Acid Phagocytic Cells Tears Natural AntibodiesTears Natural Antibodies Interferon Complement proteinsInterferon Complement proteins

Acquired ImmunityAcquired Immunity ActiveActive B Cells Immune Memory cellsB Cells Immune Memory cells T Cells AntibodiesT Cells Antibodies

Characteristics of Innate and Characteristics of Innate and Acquired ImmunityAcquired Immunity

Innate AcquiredInnate Acquired Prior exposure to the Requires exposure to Prior exposure to the Requires exposure to microbe not required microbemicrobe not required microbe Nonspecific SpecificNonspecific Specific Repeat exposure does Memory for re-Repeat exposure does Memory for re- not change response exposure not change response exposure Natural antibodies Elicited antibodiesNatural antibodies Elicited antibodies Complement system Cytotoxic LymphocytesComplement system Cytotoxic Lymphocytes Natural Killer cells Memory B and T cellsNatural Killer cells Memory B and T cells Phagocytes Plasma cells Phagocytes Plasma cells

(antibodies)(antibodies)

•The Innate Immune SystemThe Innate Immune System

Cells (N K cells) are the 1Cells (N K cells) are the 1stst line line defenders against cancer and defenders against cancer and infectious disease.infectious disease.

It initiates and improves the slower but It initiates and improves the slower but more specific acquired immune more specific acquired immune response.response.

In 1949 H. Sherwood In 1949 H. Sherwood Lawrence, Ph.D. was Lawrence, Ph.D. was

attempting to understand attempting to understand the immune response and the immune response and

how it was conveyed.how it was conveyed.

+

+ +

+ + +

- -

-

Response to an Infectious ThreatResponse to an Infectious Threat

First First ExposureExposure

Primary Primary ResponseResponse

Second Second ExposureExposure

Secondary Secondary ResponseResponse

Memory Memory CellCell

PRIMARY IMMUNE RESPONSEPRIMARY IMMUNE RESPONSE

PRIMARY IMMUNE RESPONSEPRIMARY IMMUNE RESPONSE

A cut in the skin damages cells and allows bacteria into the body A cut in the skin damages cells and allows bacteria into the body signaling an immune response from macrophages and other signaling an immune response from macrophages and other scavenger immune cells.scavenger immune cells.

Mast cells release chemicals that trigger inflammation, allowing other Mast cells release chemicals that trigger inflammation, allowing other immune cells to rush to the problem area.immune cells to rush to the problem area.

Before reinforcements arrive, macrophages and other prestationed Before reinforcements arrive, macrophages and other prestationed immune cells start attacking bacteria, chop them up into bits called immune cells start attacking bacteria, chop them up into bits called antigens.antigens.

They are then transported to lymph nodes where these macrophages They are then transported to lymph nodes where these macrophages attach to B cells and T cells. B cells begin producing antibodies attach to B cells and T cells. B cells begin producing antibodies specifically for the particular antigens or germs the body is exposed specifically for the particular antigens or germs the body is exposed to. to.

The antibodies trigger responses from certain immune cells like NK The antibodies trigger responses from certain immune cells like NK cells, macrophages and killer T cells to engulf and kill the bacteria-cells, macrophages and killer T cells to engulf and kill the bacteria-infected cells.infected cells.

Helper T cells signal the antibodies and killer T cells to go directly to Helper T cells signal the antibodies and killer T cells to go directly to the wound.the wound.

While the immune cells are taking care of the germs, other cells called While the immune cells are taking care of the germs, other cells called platelets begin healing the wound by forming clots which close the platelets begin healing the wound by forming clots which close the wound wound

SECONDARY IMMUNE SECONDARY IMMUNE RESPONSERESPONSE

SECONDARY IMMUNE SECONDARY IMMUNE RESPONSERESPONSE

A cut in the skin damages cells and allows bacteria into the body A cut in the skin damages cells and allows bacteria into the body signaling an immune response from macrophages and other signaling an immune response from macrophages and other scavenger immune cells.scavenger immune cells.

Mast cells release chemicals that trigger inflammation, allowing Mast cells release chemicals that trigger inflammation, allowing other immune cells to rush to the problem area.other immune cells to rush to the problem area.

Before reinforcements arrive, macrophages and other pre-stationed Before reinforcements arrive, macrophages and other pre-stationed immune cells start attacking bacteria, chop them up into bits called immune cells start attacking bacteria, chop them up into bits called antigens.antigens.

B cells, set in motion by previous immune responses, begin B cells, set in motion by previous immune responses, begin producing antibodies specifically for the particular antigens or germs producing antibodies specifically for the particular antigens or germs the body is exposed to. The antibodies trigger responses from the body is exposed to. The antibodies trigger responses from certain immune cells like NK cells, macrophages and killer T cells to certain immune cells like NK cells, macrophages and killer T cells to engulf and kill the bacteria-infected cells.engulf and kill the bacteria-infected cells.

Helper T cells signal the antibodies and killer T cells to go directly to Helper T cells signal the antibodies and killer T cells to go directly to the wound.the wound.

While the immune cells are taking care of the germs, other cells While the immune cells are taking care of the germs, other cells called platelets begin healing the wound by forming clots which close called platelets begin healing the wound by forming clots which close the wound.the wound.

Secondary Immune Secondary Immune ResponseResponse

Transfer FactorTransfer Factor

1. Early Recognition1. Early Recognition

2. Quick Response2. Quick Response

3. Massive Response3. Massive Response

4. Allows Us to Win “The 4. Allows Us to Win “The Numbers Game”Numbers Game”

5. Provides Resistance5. Provides Resistance

6. Resistance Equals 6. Resistance Equals ImmunityImmunity

7. Immunity Provides 7. Immunity Provides ProtectionProtection

8. Key to Immunity - 8. Key to Immunity - Memory MoleculeMemory Molecule

Memory Molecule Is:Memory Molecule Is:

SOURCES OF TRANSFER FACTORSOURCES OF TRANSFER FACTOR

BLOODBLOOD(1949 LAWRENCE)(1949 LAWRENCE)

WHITE BLOODCELLS CALLED WHITE BLOODCELLS CALLED LYMPHOCYTES ARE LYMPHOCYTES ARE REMOVED FROM BLOOD REMOVED FROM BLOOD AND TRANSFER FACTORS AND TRANSFER FACTORS ARE REMOVED FROM ARE REMOVED FROM THEM. THEM.

EXPENSIVE BUTEXPENSIVE BUTEFFECTIVEEFFECTIVE.. NOT NOT PRACTICAL FORPRACTICAL FORGENERAL USE.GENERAL USE.

COLOSTRUMCOLOSTRUM(1989 WILSON/PADDOCK)(1989 WILSON/PADDOCK)

FIRST MATERNAL MILK FIRST MATERNAL MILK PRODUCED RIGHT AT AND PRODUCED RIGHT AT AND AFTER BIRTH. PATENTED AFTER BIRTH. PATENTED SELECTIVE FILTRATION SELECTIVE FILTRATION METHOD PERFECTED IN METHOD PERFECTED IN 1989 WHICH REMOVES 1989 WHICH REMOVES TRANSFER FACTORS FROM TRANSFER FACTORS FROM COLOSTRUM. COLOSTRUM.

ECONOMICAL ANDECONOMICAL ANDEFFECTIVE.EFFECTIVE. PRACTICALPRACTICAL

FOR GENERAL USE.FOR GENERAL USE.

Source of Transfer FactorSource of Transfer Factor

NO PESTICIDESNO PESTICIDES NO ANTIBIOTICSNO ANTIBIOTICS NO HORMONESNO HORMONES

ULTRAULTRA FILTRATIONFILTRATION

FILTER

From the Cow to YouFrom the Cow to YouTransfer Factor™ QualityTransfer Factor™ Quality

Quality Assurance and Quality Assurance and Product Safety Product Safety

CommunicationsCommunicationsDr. Rick BennettDr. Rick Bennett

The TF Farms and CowsThe TF Farms and Cows Farms in the Farms in the

United StatesUnited States ““Grade A” Grade A”

DairiesDairies State and State and

Federal quality Federal quality controlscontrols

Pasture and Pasture and Corral fedCorral fed

Colostrum ProductionColostrum Production

Colostrum Colostrum “milked” for the “milked” for the first day +first day +

Baby calves get Baby calves get plentyplenty

Harvested as for Harvested as for Grade A MilkGrade A Milk

Frozen on farmFrozen on farm

Colostrum TF ProcessingColostrum TF Processing Frozen then Frozen then

thawedthawedat plantat plant

DefattedDefatted Batch Pasteurized Batch Pasteurized

(LTLT)(LTLT) Ultra-filtered to Ultra-filtered to

concentrate concentrate Transfer Factor™Transfer Factor™

Low temp. sprayed Low temp. sprayed drieddried

™

Quality Assurance: HACCPQuality Assurance: HACCP

• Known hazards

• Documented interventions

• Electronic monitoring

True QA !

Transfer Factor Safety Transfer Factor Safety Communications Key PointsCommunications Key Points USFDA Grade A DairiesUSFDA Grade A Dairies USDA and State Approved Food USDA and State Approved Food

Processing PlantsProcessing Plants Pasteurized Colostrum and TF Ultra-Pasteurized Colostrum and TF Ultra-

filtrate (3x Microbial safety control)filtrate (3x Microbial safety control) Antibiotics cannot be legally used in Antibiotics cannot be legally used in

“milking” cows- Milk and colostrum “milking” cows- Milk and colostrum routinely testedroutinely tested

rBST not “generally” used on TF rBST not “generally” used on TF farmsfarms

Mad Cow disease NOT present in USMad Cow disease NOT present in US

™

Transfer FactorTransfer Factor Quality Quality Assured, Ready for Product Assured, Ready for Product

Formulation and YouFormulation and You

™

IMPORTANT POINTSIMPORTANT POINTS DAIRY CATTLE DAIRY CATTLE

PRODUCE LARGE PRODUCE LARGE AMOUNTS OF AMOUNTS OF COLOSTRUM-MORE COLOSTRUM-MORE THAN THE CALF THAN THE CALF NEEDS.NEEDS.

TRANSFER TRANSFER FACTORS ARE THE FACTORS ARE THE SAME FOR ALL SAME FOR ALL SPECIES. SPECIES.

HUMAN AND COW TRANSFER HUMAN AND COW TRANSFER FACTORS ARE MOLECULARLY FACTORS ARE MOLECULARLY

IDENTICAL!!!IDENTICAL!!!

WHY NOT JUST COLOSTRUM?WHY NOT JUST COLOSTRUM?

COLOSTRUMCOLOSTRUM1.1. WATERWATER2.2. VITAMINS/MINERALSVITAMINS/MINERALS3.3. PROTEINPROTEIN4.4. FATFAT5.5. CARBORHYDRATES CARBORHYDRATES

(LACTOSE)(LACTOSE)6.6. IMMUNOGLOBULINS IMMUNOGLOBULINS

(SPECIES-SPECIFIC (SPECIES-SPECIFIC ANTIBODIES)ANTIBODIES)

7.7. SLIGHT GROWTH SLIGHT GROWTH HORMONEHORMONE

8.8. TRANSFER FACTORSTRANSFER FACTORS

TRANSFER FACTOR™TRANSFER FACTOR™1.1. TRANSFER FACTORSTRANSFER FACTORS

IT IS ESTIMATED TO IT IS ESTIMATED TO TAKE 45 GM OF TAKE 45 GM OF

COLOSTRUM (OR 45,000 COLOSTRUM (OR 45,000 MG) TO GET THE MG) TO GET THE

EQUIVALENT TRANSFER EQUIVALENT TRANSFER FACTORS IN 600 MG OF FACTORS IN 600 MG OF

4LIFE™ TRANSFER 4LIFE™ TRANSFER FACTOR™.FACTOR™.

CHARACTERISTICS OF TRANSFER FACTORSCHARACTERISTICS OF TRANSFER FACTORS

1.1. VERY SMALL POLYPEPTIDES (PROTEINS)VERY SMALL POLYPEPTIDES (PROTEINS)2.2. MOLECULAR WEIGHT < 6000 DALTONSMOLECULAR WEIGHT < 6000 DALTONS3.3. THE SAME FOR ALL SPECIESTHE SAME FOR ALL SPECIES4.4. STABLE EVEN IN ACID ENVIRONMENT (NOT HYDROLYZED)STABLE EVEN IN ACID ENVIRONMENT (NOT HYDROLYZED)5.5. ABSORABLE IN ALL-AGED RECIPIENTSABSORABLE IN ALL-AGED RECIPIENTS6.6. NON-ALLERGENIC DUE TO SMALL SIZENON-ALLERGENIC DUE TO SMALL SIZE7.7. HALF-LIFE THOUGHT TO BE < THREE WEEKSHALF-LIFE THOUGHT TO BE < THREE WEEKS8.8. ORAL ADMINISTRATION THOUGHT TO BE MOST ORAL ADMINISTRATION THOUGHT TO BE MOST

EFFECTIVE ROUTEEFFECTIVE ROUTE9.9. NON-TOXICNON-TOXIC

REMEMBER #3 – TRANSFER FACTORS REMEMBER #3 – TRANSFER FACTORS ARE THE SAME FOR ALL SPECIES!!ARE THE SAME FOR ALL SPECIES!!

PROPERTIES OF TRANSFER FACTORSPROPERTIES OF TRANSFER FACTORS(3 FRACTIONS)(3 FRACTIONS)

INDUCERINDUCER TRIGGERS A GENERAL STATETRIGGERS A GENERAL STATEFRACTIONFRACTION OF READINESS IN THE IMMUNEOF READINESS IN THE IMMUNE SYSTEMSYSTEM

ANTIGENANTIGEN AN ARRAY OF CRITICAL TAGSAN ARRAY OF CRITICAL TAGSSPECIFICSPECIFIC USED BY THE IMMUNE SYSTEMUSED BY THE IMMUNE SYSTEMFRACTIONFRACTION TO IDENTIFY A HOST OF ENEMYTO IDENTIFY A HOST OF ENEMY

MICROBESMICROBES

SUPPRESSORSUPPRESSOR DOWN-REGULATES THE IMMUNEDOWN-REGULATES THE IMMUNEFRACTIONFRACTION RESPONSE ONCE THE THREATRESPONSE ONCE THE THREAT

IS DEFEATEDIS DEFEATED

Benefits of Transfer FactorBenefits of Transfer Factor Emergence of new viruses or resurfacing of old pathogens.Emergence of new viruses or resurfacing of old pathogens. Successful use in viral, parasitic, fungal, malignant, neurological Successful use in viral, parasitic, fungal, malignant, neurological

and autoimmune diseases.and autoimmune diseases. Cases of atopic dermatitis, herpes zoster ophthalmicusCases of atopic dermatitis, herpes zoster ophthalmicus l600 pts, good to excellent results in viral, cancer, fungal, CFS, l600 pts, good to excellent results in viral, cancer, fungal, CFS,

AIDS and autoimmune diseases with no acute or chronic toxicity.AIDS and autoimmune diseases with no acute or chronic toxicity. Congenital immunodeficiency, IgA, IgECongenital immunodeficiency, IgA, IgE Antibiotic-resistant infectionsAntibiotic-resistant infections AsthmaAsthma PsoriasisPsoriasis SenilitySenility Hepatitis BHepatitis B The use of transfer factor in the prevention of illness and the The use of transfer factor in the prevention of illness and the

maintenance of health is its greatest potential benefit and its maintenance of health is its greatest potential benefit and its safety when used chronically has been well demonstrated.safety when used chronically has been well demonstrated.

Excellent safety record with no adverse side effect even when Excellent safety record with no adverse side effect even when administered in extreme excess or over several years in all age administered in extreme excess or over several years in all age groups.groups.

TF in the Intensive Care UnitTF in the Intensive Care Unit1515

60 patients60 patients immuno-deficiencies, diabetic patientsimmuno-deficiencies, diabetic patients no time to wait for tests no time to wait for tests 1 unit of TF 3/d for 3 days oral, IM or IV1 unit of TF 3/d for 3 days oral, IM or IV improved response to conventional improved response to conventional

therapytherapy reduced hospitalization timereduced hospitalization time

TF and Severe Pediatric TF and Severe Pediatric InfectionsInfections1212

45 patients45 patients average age 4.2 yrsaverage age 4.2 yrs unresponsive to conventional therapyunresponsive to conventional therapy 43 cases reached remission43 cases reached remission improvement even in the 2 other improvement even in the 2 other

cases in spite of congenital IgA and cases in spite of congenital IgA and IgG deficiencyIgG deficiency

Atopic Dermatitis with Atopic Dermatitis with Transfer Factor or Cyclosporin ATransfer Factor or Cyclosporin A

30 patients30 patients Cellular immune deficiency Cellular immune deficiency Unresponsive to conventional therapyUnresponsive to conventional therapy Both groups lowered eosinophilsBoth groups lowered eosinophils Cyclosporin A lowered CD4 (helper)Cyclosporin A lowered CD4 (helper) TF raised CD8 (suppressor)TF raised CD8 (suppressor)

TRANSFER FACTORTRANSFER FACTOR

More than 3,000 publicationsMore than 3,000 publications Clinical trialsClinical trials International Congress on Transfer International Congress on Transfer

Factor (XI) Factor (XI)

US PATENTSUS PATENTS [54] FOOD AND THE METHOD OF EXTRACTING THE SAME FROM COLOSTRUM AND MILK [75] Inventors: Mary E. Collins; Robert A. Collins, both of Waukon, Iowa [73] Assignee: Impro Porducts, Inc., Wankson, Iowa [21] Appl. No.: 276,230 [22] Filed:Jun. 22, 1981 Related U.S. Application Data [63] Continuation-in-part of Ser. No. 154,502, May 29, 1980, abandoned. [51] Int. Cl.4............................................... 4A61K 39/00 [52] U.S. Cl. ........................................ 424/85; 426/583; 426/491 [53] Field of Search ...................426/580, 583, 41, 431, 426/491, 495, 657; 424/85, 86, 87 [56] References Cited: U.S. PATENT DOCUMENTS 3,128,230 4/1964 Helabach...................424/85 3,646,193 2/1972 Michaelson et al. ......424/85 3,911,108 10/1975 Siagla.........................424/86 3,984,539 10/1976 Khouw et al...........424/85 X 4,051,235 9/1977 Plymater ....................424/85 PATENT PURPORTED BY MATOL United States Patent [19] [11] 4,402,938 Collins et al. [45] Sep. 6, 1983 4,138,501 2/1979 Chareron et al. .......426/239 4,284,623 5/1981 Beck ......................... 424/85 OTHER PUBLICATIONS Webb, B.H., “Fundamentals of Dairy Chemistry”, The Avi Publ. Co., Inc., Westport, Conn., 1965, pp. 10 and 416. Butler, J.H., :37 The Occurrence of Immunoglobulin Fragments, Two Types of Lactoferrin and a Lac- to- Ferrin-lgG2 Complex in Bovine Colostral and Milk Whey”, Biochemists et Biophsicis Acta, 295, (1973), pp. 341-351. McDonough, F.E., et al., “Protein Concentrate from Cheese Whey by Ultrafiltration”, J. Dairy Sci., vol. 54, No. 10, Oct. 1971, pp. 1406-1409. Primary Examiner -- Robert A Yoncoakie Attorney, Agent, or Firm -- Ira Milton Jones [57] ABSTRACT This invention provides a new and useful food factor for use as a nutritional supplement for animals, which product comprises whey obtained from colostrum and milk as it comes from selected cows or other ungulates, and containing an active fraction having a molecular weight on the order of 1200 or less. 6 Claims, No Drawings [54] PROCESS FOR OBTAINING TRANSFER FACTOR FROM COLOSTRUM, TRANSFER FACTOR SO OBTAINED AND USE THEREOF [75] Inventors: Gregory B. Wilson; Gary V. Paddock, both of Mount Pleasant, S.C. [73] Assignee: Amtron, Inc., Charleston, S.C. [21] Appl. No.: 670,596 [22] Filed: Nov. 15, 1984 Related U.S. Application Data [63] Continuation-in-part of Ser. No. 554,921, Nov. 25, 1983, abandoned. [51] Int. Cl.4 ........................ A61K 39/00; A61K 39/02; A61K 39/12; C07H 15/12 [52] U.S. Cl. ......................................530/344; 530/300; 536/22; 536/23; 536/24; 536/27; 514/2; 514/7; 514/8; 424/88; 424/89; 424/92; 424/105; 435/68 [58] Field of Search....................... 424/95, 105, 88, 89, 424/92, 93; 514/2, 7, 8; 530/350, 300, 832, 833, 344, 300; 536/22, 23, 24, 27 [56] References Cited PUBLICATIONS France et al Clin Res, vol. 28 863 A 1981 “Transfer Factor from Human Colostrum and Breast Milk Lymphocytes”. Ruben et al Clin Res vol. 27(4) 1979 698 A “Cell Medicated immunity to influenza A virus and influenza B virus in human colostrum and milk.” Meggs et al Am J. Obstet Gynecol vol. 133(6) 1979, pp. 703-707 “In-vitro Stimulation of human colostral lymphocytes by cytomegalovirus”. Parmely et al J. Dairy Science vol. 60(4) 1977 pp. 4LIFE TRANSFER FACTOR PATENT United States Patent [19] [11] Patent Number: 4,816,563 Wilson et al. [45] Date of Patent: Mar. 28, 1989 655-665 “Colostral cell medicated immunity and the concept of a common secretory immune system”. Schlesinger et al Lancet vol. 2 1977 pp. 529-532 “Evidence for transmission of lymphocytes response to tuberculin by brest feeding”. Wilson et al Immunobiology of Transfer Factor 1983 Kirkpatrick, Colt et al editors p. 331. Wilson et al. Immunology Today vol. 4, p. 157. Primary Examiner -- Thomas G. Wiseman Assistant Examiner -- Robin L. Teskin Attorney, Agent, or Firm -- John P. White; John J. Santalone [57] ABSTRACT Antigen specific excreted transfer factor may be ob-tained by collecting material, e.g. colostrum or milk, secreted by the mammary gland of a suitable lactating mammal, e.g. a cow having immunity to the antigen under suitable conditions such that materials which interfere with transfer factor efficacy are removed so as to obtain transfer factor. Colostrum or milk so collected may be used directly, typically after sterilization, or may be treated to further concentrate and/or purify transfer factor. Treatment to yield colostral whey con-taining transfer factor is presently the preferred method for obtaining transfer factor for use in conferring immu-nity against diseases associated with antigens for which the transfer factor is specific. Cell-associated transfer factor specific for an antigen may also be obtained by incubation release from, or lysis of, cells obtained from the collected material. An alternative method for ob-taining transfer factor is to recover it from the mammary tissue of a suitable lactating mammal. The transfer factor may be used in edible compositions and in phar-maceutical or veterinary compositions and in methods for conferring immunity in a human or lower animal to a disease associated with the antigen. The transfer factor may then be used to prevent or treat the disease. 28 Claims, No Drawings

IMPORTANCE OF TRANSFER FACTORIMPORTANCE OF TRANSFER FACTOR((ORIGINS OF DISEASE)ORIGINS OF DISEASE)

THREATSTHREATS

FROM OUTSIDEFROM OUTSIDE

1. ALLERGIES1. ALLERGIES

2. INFECTIONS2. INFECTIONS

THREATSTHREATS

FROM WITHINFROM WITHIN

1. AUTO-IMMUNE1. AUTO-IMMUNE

2. CANCER2. CANCER

MAJORITY OF DISEASESMAJORITY OF DISEASES

1. ALLERGIES1. ALLERGIES

2. INFECTIONS2. INFECTIONS

3. AUTO-IMMUNE3. AUTO-IMMUNE

4. CANCER4. CANCER

ARE IMMUNE SYSTEMARE IMMUNE SYSTEMDYSFUNCTIONSDYSFUNCTIONS

IF YOUR IMMUNE SYSTEM IS:IF YOUR IMMUNE SYSTEM IS:

UNDERACHIEVINGUNDERACHIEVING

1.1. INFECTIONINFECTION2.2. CANCERCANCER

NEED TO:NEED TO:

STIMULATESTIMULATE

OVERACHIEVINGOVERACHIEVING

1.1. ALLERGIESALLERGIES2.2. AUTO-IMMUNEAUTO-IMMUNE

NEED TO:NEED TO:

BALANCEBALANCE

Transfer Factor™ is anTransfer Factor™ is an

immunomodulator meaning it is bestimmunomodulator meaning it is best

utilized to balance the immune systemutilized to balance the immune system

response. Remember Transferresponse. Remember Transfer

Factor™ has both INDUCER and Factor™ has both INDUCER and

SUPPRESSOR fractions.SUPPRESSOR fractions.

Immune Immune Functionality's:Functionality's:

ENHANCERENHANCER

SUPPRESSOR

ANTIGEN SPECIFIC

TRANSFER FACTOR

TRANSFER FACTOR PLUS™TRANSFER FACTOR PLUS™

22NDND GENERATION FORMULATION GENERATION FORMULATION

DESIGNED BY:DESIGNED BY:

WILLIAM HENNEN, PH.D.WILLIAM HENNEN, PH.D.

DIRECTOR OF R&D 4LIFE™ DIRECTOR OF R&D 4LIFE™ RESEARCHRESEARCH

IMMUNO-STIMULANTIMMUNO-STIMULANT


INGREDIENTSINGREDIENTS

1.1. TRANSFER FACTOR™TRANSFER FACTOR™2.2. CORDYCEPSCORDYCEPS3. GLUCANS3. GLUCANS

(YEAST, MAITAKE, SHIITAKE)(YEAST, MAITAKE, SHIITAKE)

4. MANNANS4. MANNANS(FROM ALOE VERA)(FROM ALOE VERA)

5. IP-65. IP-66. THYMIC FACTORS6. THYMIC FACTORS

LymphocytesLymphocytes

T cells : T cells : helper T cell, cytotoxic T cells, helper T cell, cytotoxic T cells, DTH T cellsDTH T cells

B cells : B cells : pro-B cell, pre-B cell, immature pro-B cell, pre-B cell, immature B cell, B cell,

mature B cellmature B cell NK cells : CD56NK cells : CD56brightbright, CD56, CD56dimdim

NKT cells = NK like T cellsNKT cells = NK like T cells

o LAK cell = lymphokine activated killer LAK cell = lymphokine activated killer cellscells

( T-LAK, NK-LAK)( T-LAK, NK-LAK)o TIL cell = tumor-infiltrating lymphocytesTIL cell = tumor-infiltrating lymphocytes

Pivotal role of NK cells in the immune Pivotal role of NK cells in the immune system system

NK cellsNK cells

NKT NKT cellscells

Innate immunity vs. adaptive Innate immunity vs. adaptive immunityimmunity

Innate (non-specific):Innate (non-specific):

- skin, monocytes/macrophage - skin, monocytes/macrophage system, NK cells etc.system, NK cells etc.

Adaptive (specific):Adaptive (specific):

- humoral immunity (B cells)- humoral immunity (B cells)

- cellular immunity (T cells)- cellular immunity (T cells)

Interplay of Innate and Adaptive Interplay of Innate and Adaptive ImmunityImmunity

The complement system is the merging The complement system is the merging point of innate and adaptive immunity. NK point of innate and adaptive immunity. NK cells also produce a number of cytokines cells also produce a number of cytokines (messenger molecules) that are potent (messenger molecules) that are potent regulator of T cells.regulator of T cells.

Dendritic cells, like macrophages, capture Dendritic cells, like macrophages, capture foreign antigens, present them to other foreign antigens, present them to other immune cells and trigger antibody immune cells and trigger antibody production. They also produce cytokines in production. They also produce cytokines in response to enveloped viruses (herpes response to enveloped viruses (herpes simplex and HIV).simplex and HIV).

Innate immunity i.e. macrophageMediatedwith little antibody

Adaptive immunity i.e. antibodies produced and isotype class switching

Infected cell is killed

Innate Humoral

CTL

Cytotoxicity

Th1 Th2

CD4-helper CD8-suppressor

THYMUS

http://www.health.auckland.ac.nz/courses/Biosci357/LecturesWeb/357Lecture11.htm

Suppressor

NKT cells (human)NKT cells (human) Restricted TCR repertorie : VRestricted TCR repertorie : VJJQQ Recognize MHC class I Recognize MHC class I ––like CD1like CD1 FrequencyFrequency

- PBL : 0.1 ~ 0.5%- PBL : 0.1 ~ 0.5%

- Liver : 4 - Liver : 4 –– 5% 5% Cytokine productionCytokine production

-- type 1 : IFN-type 1 : IFN-, IL-2, TNF-, IL-2, TNF-anti-anti-cancer effectcancer effect

-- type 2 : IL-4, IL-5, IL-10 type 2 : IL-4, IL-5, IL-10 prevent prevent autoimmune diseaseautoimmune disease

Natural Killer Cell (I)Natural Killer Cell (I)

10 10 –– 20% of lymphocytes 20% of lymphocytes in in circulating bloodcirculating blood

Natural resistance against Natural resistance against tumors and virus infections etc.tumors and virus infections etc.

Morphology : Large Granular Morphology : Large Granular Lymphocytes Lymphocytes (LGL) (LGL)

Marker : CD3Marker : CD3--CD56CD56++CD16CD16+/-+/-

Killer CellsKiller Cells They target cells that are missing the self marker They target cells that are missing the self marker

that identifies a cell as one of our own. Foreign cells that identifies a cell as one of our own. Foreign cells without self markers are attacked.without self markers are attacked.

Low NK cell activity: cancer, congenital or acquired Low NK cell activity: cancer, congenital or acquired immunodeficiencies, severe viral infections, immunodeficiencies, severe viral infections, autoimmune diseases, behavioral disorders, several autoimmune diseases, behavioral disorders, several genetic disorders, chronic illness and infections.genetic disorders, chronic illness and infections.

The young, the old and the stressed are more The young, the old and the stressed are more susceptible to immunologic breakdown. This may susceptible to immunologic breakdown. This may allow tumors to grow faster.allow tumors to grow faster.

Chronic fatigue immune dysfunction syndromeChronic fatigue immune dysfunction syndrome (CFIDS) is associated with persistently low NK (CFIDS) is associated with persistently low NK

activityactivity

Natural Killer Cell (II)Natural Killer Cell (II)

Cytolytic mechanism : spontaneously Cytolytic mechanism : spontaneously killing killing –– Ab dependent Cellular Ab dependent Cellular Cytotoxicity (ADCC)Cytotoxicity (ADCC)

Cytolytic mediatros : Cytolytic mediatros : perforin/granzyme, Fas-perforin/granzyme, Fas-

ligand/Fas, TNF-ligand/Fas, TNF-, NO, NO Self vs. non-self : MHC class I Self vs. non-self : MHC class I

negative signalnegative signal

Natural Killer Cell (III)Natural Killer Cell (III)

NK cell activation : NK cell activation : IFN-IFN-, IL-2, , IL-2, IL-12, IL-12, IL-18IL-18 etc.etc.

NK-cell precursor NK-cell precursor IL-15 IL-15 Mature Mature NK cellNK cell

NK cell subsets : CD56NK cell subsets : CD56bright bright , CD56, CD56dimdim

CD56 dim NK cellsCD56 dim NK cells Majority (90%) of NK cellsMajority (90%) of NK cells >95% of cells are CD16>95% of cells are CD16bright bright ADCC ADCC are more toxic than CD56 bright are more toxic than CD56 bright

cells.cells. produce low levels of cytokines.produce low levels of cytokines. are more granular than CD56 bight are more granular than CD56 bight

cells.cells. have relatively low proliferative have relatively low proliferative

capacity.capacity. are less responsive to IL-2 induced are less responsive to IL-2 induced

proliferation. proliferation.

KIR: killer cell Ig-like receptorKIR: killer cell Ig-like receptor MHC: major histocompatibility complexMHC: major histocompatibility complex CD: clusters of differentionCD: clusters of differention CD94: C-type-lectin-inhibitory receptorCD94: C-type-lectin-inhibitory receptor NKG2:inhibitory variantsNKG2:inhibitory variants NCR: natural cytotoxicity receptorsNCR: natural cytotoxicity receptors ILT: Ig-like transcriptsILT: Ig-like transcripts APC: antigen-presenting cellsAPC: antigen-presenting cells

CD56 bright NK cellsCD56 bright NK cells 10% of NK cells10% of NK cells have the capacity to produce abundant have the capacity to produce abundant

cytokines.cytokines. express high affinity IL-2 receptor (IL-2Rexpress high affinity IL-2 receptor (IL-2R

low doses of IL-2 low doses of IL-2 proliferation, proliferation, enhancement of cytotoxicity enhancement of cytotoxicity

major NK-cell subset in the uterus of a major NK-cell subset in the uterus of a pregnant womanpregnant woman

are among the first lymphocytes to are among the first lymphocytes to repopulate the repopulate the peripheral blood following peripheral blood following BMT.BMT.

clinical interest clinical interest very low doses of IL-2 very low doses of IL-2 expand expand selectively this cell in cancer and HIV selectively this cell in cancer and HIV patients.patients.

CYTOKINESCYTOKINES

IFN: InterferonIFN: Interferon TNF: tumor necrosis factorTNF: tumor necrosis factor IL: interleukinIL: interleukin TGF: transforming growth factorsTGF: transforming growth factors CSF: hematopoietic colony-CSF: hematopoietic colony-

stimulating factorsstimulating factors

NK cells in diseaseNK cells in disease

Cancer, TuberculosisCancer, Tuberculosis

- reduced NK cytotoxicity- reduced NK cytotoxicity AIDSAIDS

- low concentration of NK - low concentration of NK cellscells

- reduced NK cytotoxicity- reduced NK cytotoxicity AlzheimerAlzheimer’’s diseases disease

- increased NK cytotoxicity- increased NK cytotoxicity

NK cells and immunotherapyNK cells and immunotherapy

Tumor therapyTumor therapy Adv.Adv.

- activated NK cells are readily - activated NK cells are readily available for cancer available for cancer therapy.therapy.

- expand rapidly in culture without - expand rapidly in culture without prior prior sensitization.sensitization.

Immunotherapy/chemotherapyImmunotherapy/chemotherapy Immunotherapy/genetherapyImmunotherapy/genetherapy

NK cells vs. ethanolNK cells vs. ethanol

Diminished activation of NK cell lytic functionDiminished activation of NK cell lytic function

- decreased production of and response to IFN-- decreased production of and response to IFN-alphaalpha- decreased levels of granzyme B and perforin- decreased levels of granzyme B and perforin

NK cells vs. agingNK cells vs. aging

Impaired NK cytotoxicityImpaired NK cytotoxicity

- decreased proliferative response - decreased proliferative response to IL-2to IL-2

the expansion of a mature NK cellsthe expansion of a mature NK cells

Stress: NK cytotoxicity is Stress: NK cytotoxicity is suppressed.suppressed.

NK cells vs. training NK cells vs. training

Increased the percentage of NK cellsIncreased the percentage of NK cells

- increased NK cell activity in the - increased NK cell activity in the group on thegroup on the

carbohydrate-rich dietcarbohydrate-rich diet

- decreased NK cell activity in the - decreased NK cell activity in the group on thegroup on the

fat-rich dietfat-rich diet

JANA STUDY* – WINTER 1999JANA STUDY* – WINTER 1999 *DARRYL M. SEE, M.D., UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA *DARRYL M. SEE, M.D., UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

196 PRODUCTS STUDIED WITH OVER 196 PRODUCTS STUDIED WITH OVER 400 INGREDIENTS400 INGREDIENTS

STUDY WAS DESIGNED TO MEASURE STUDY WAS DESIGNED TO MEASURE NATURAL KILLER CELL ACTIVITYNATURAL KILLER CELL ACTIVITY

NK CELLS ARE OUR FIRST LINE OF NK CELLS ARE OUR FIRST LINE OF DEFENSEDEFENSE

JANA TEST RESULTSJANA TEST RESULTS

PRODUCTPRODUCT

1.1. NONINONI2.2. ALOE VERAALOE VERA3.3. ENDOCRINE FORMULAENDOCRINE FORMULA4.4. PHYTONUTRIENT FORMULAPHYTONUTRIENT FORMULA5.5. BOVINE COLOSTRUMBOVINE COLOSTRUM6.6. CORDYCEPSCORDYCEPS7.7. SHIITAKESHIITAKE8.8. ECHINACEA (19% USE)ECHINACEA (19% USE)9.9. PLANT SUGARS FORMULAPLANT SUGARS FORMULA10.10. IP-6IP-611.11. TRANSFER FACTOR™TRANSFER FACTOR™12.12. TRANSFER FACTOR PLUS™TRANSFER FACTOR PLUS™

% RISE OVER BASELINE% RISE OVER BASELINE

1. 15%1. 15%2. 15%2. 15%3. 16%3. 16%4. 21%4. 21%5. 23%5. 23%6. 28%6. 28%7. 42%7. 42%8. 43%8. 43%9. 48%9. 48%10. 49%10. 49%

11. 11. 103%103% 12. 12. 248%248%

TRANSFER FACTOR TRANSFER FACTOR PLUS ADVANCED PLUS ADVANCED

FORMULAFORMULA

438% Increase in NK cell 438% Increase in NK cell activity!!!activity!!!

In a historic move, the Ministry of Health and Social Development of the Russian Federation has given approval to a dietary supplement for use in comprehensive health care practice to 4Life. The approval opens the way for the use of these immune modulators in Russian hospitals.

Start prognosis: Patients had 3.7 months to live. Results after six months: 16 out of the 20 patients studied are in remission, either improving or

in stable condition.

Conducted by Dr. Darryl SeeOn Stage 4 cancer patients

"There is no other product in a nutritional substance, nor a drug, that has this kind of power and ability to affect our immune system. With the increase of killer viruses, mutated germs, super-resistant germs, and food contaminations, our only hope and defense, must lie within our own immune system."

-- Darryl See, MD

Associate Clinical Professor WHO ( World Health Organization) Western Europe, Dr. See received his degree from the University of California, Irvine. Academic appointments include: Assistant/Associate Clinical Professor of Medicine: Investigator, California Collaborative Treatment Group: and Infectious Disease Consultant, Liver Transplantation Service. He has received contracts, grants, and research awards from Pfizer Pharmaceuticals, Upjohn Pharmaceuticals, Roche Molecular Systems, Harvard Biotechnology, National Institutes of Health, Department of Defense, and more….


SEEKING STIMULATIONSEEKING STIMULATION INFECTIONINFECTION

CANCERCANCER

PREVENTIONPREVENTION

TRANSFER FACTOR™TRANSFER FACTOR™SEEKING BALANCESEEKING BALANCE

ALLERGIESALLERGIES

AUTO-IMMUNE DISEASESAUTO-IMMUNE DISEASES

SEEKING DOWN-REGULATIONSEEKING DOWN-REGULATION

COMMONALITY HUMAN/BOVINE COMMONALITY HUMAN/BOVINE PATHOGENSPATHOGENS

HUMAN PATHOGEN OR DISEASEHUMAN PATHOGEN OR DISEASE BOVINE PATHOGENBOVINE PATHOGEN

BACTERIABACTERIA BACTERIABACTERIA

TRAVELERS DIARRHEA (TRAVELERS DIARRHEA (E. COLIE. COLI)) VERYVERY TOXIGENIC TOXIGENIC E. COLIE. COLIVERYVERY CAMPYLOBACTER JEJUNICAMPYLOBACTER JEJUNI

BLOODY DIARRHEA/HEMOLYTIC BLOODY DIARRHEA/HEMOLYTIC INCREASINGINCREASING E. COLIE. COLI O157:H7 VEROTOXIC O157:H7 VEROTOXICUREMIAUREMIA

SALMONELLOSIS & TYPHOID FEVERSALMONELLOSIS & TYPHOID FEVER COMMONCOMMON SALMONELLA THYPHIMURIUMSALMONELLA THYPHIMURIUM,,SALMONELLA TYPHOSASALMONELLA TYPHOSA DUBLINDUBLIN

DIARRHEA, FROM FOOD AND WATERDIARRHEA, FROM FOOD AND WATER VERYVERY CAMPYLOBACTER JEJUNICAMPYLOBACTER JEJUNICAUSING GUILLANE BARRE SYN.CAUSING GUILLANE BARRE SYN.

LEPTOSPIROSIS (KIDNEY FAILURE)LEPTOSPIROSIS (KIDNEY FAILURE) RARERARE LEPTOSPIRA (MANY SEROVARS)LEPTOSPIRA (MANY SEROVARS)UNDULANT FEVER UNDULANT FEVER RARERARE BRUCELLA ABORTUSBRUCELLA ABORTUS

((BRUCELLA ABORTUSBRUCELLA ABORTUS))CLOSTRIDIAL INFECTIONCLOSTRIDIAL INFECTION COMMONCOMMON CLOSTRIDIA (MANY SPECIES)CLOSTRIDIA (MANY SPECIES)

(NON(NON TETANUS) TETANUS) C. DIFFICILEC. DIFFICILEMYCOBACTERIUM INFECTIONSMYCOBACTERIUM INFECTIONS MYCOBACTERIUM SPECIESMYCOBACTERIUM SPECIES

AVIUMAVIUM RARERAREBOVISBOVIS RARERARETUBERCULOSISTUBERCULOSIS VERYVERYJOHNEI, CROHN’S DISEASEJOHNEI, CROHN’S DISEASE COMMONCOMMON (MOST COMMON IN JERSEY (MOST COMMON IN JERSEY CATTLE)CATTLE)

COMMONALITY CONTINUEDCOMMONALITY CONTINUEDHUMAN PATHOGEN OR DISEASE (CONT.)HUMAN PATHOGEN OR DISEASE (CONT.) BOVINE PATHOGEN (CONT.)BOVINE PATHOGEN (CONT.)

BACTERIA (CONT.)BACTERIA (CONT.) BACTERIA (CONT.)BACTERIA (CONT.)

STAPHYLOCOCCAL SUPER INFECTIONSSTAPHYLOCOCCAL SUPER INFECTIONS COMMONCOMMON STAPH. AUREUSSTAPH. AUREUSSTREPTOCOCCAL INFECTIONSSTREPTOCOCCAL INFECTIONS COMMONCOMMON STREPTOCOCCUSSTREPTOCOCCUS

ENDOCARDITISENDOCARDITIS COMMONCOMMON BETA STREPTOCOCCUS BETA STREPTOCOCCUSSUPERINFECTIONSUPERINFECTION INCREASINGINCREASING S. PYOGENESS. PYOGENESS. PYOGENESS. PYOGENES INCREASINGINCREASING

ENTEROCOCCIENTEROCOCCI COMMONCOMMON ENTEROCOCCI (MOST SPECIES & VRE) ENTEROCOCCI (MOST SPECIES & VRE) HOSPITAL AND VRE STRAINSHOSPITAL AND VRE STRAINS

LISTERIOSIS AND ABORTIONLISTERIOSIS AND ABORTION RARERARE LISTERIA MONOCYTOGENESLISTERIA MONOCYTOGENESNEONATAL MENINGEOENCEPHALITISNEONATAL MENINGEOENCEPHALITIS RARERARE

HELIOBACTER PYLORIHELIOBACTER PYLORI (ULCERS) (ULCERS) COMMONCOMMON BOVINE AND PORCINEBOVINE AND PORCINE ASSOCIATIONASSOCIATION

VIRUSESVIRUSES VIRUSESVIRUSES

INFLUENZAINFLUENZA COMMONCOMMON INFLUENZA VIRUSINFLUENZA VIRUSPNEUMONIA (PNEUMONIA (RESP. SYNCYTIAL VIRUSRESP. SYNCYTIAL VIRUS)) COMMONCOMMON BOVINE RESP. SYNCYTIAL VIRUSBOVINE RESP. SYNCYTIAL VIRUSPAPILLOMA, CONDYLOMAYAPAPILLOMA, CONDYLOMAYA COMMONCOMMON BOVINE PAPILLOMA VIRUSBOVINE PAPILLOMA VIRUSVIRUS DIARRHEAVIRUS DIARRHEA COMMONCOMMON BOVINE VIRUS DIARRHEABOVINE VIRUS DIARRHEA

ROTAVIRUSROTAVIRUS ROTAVIRUS ROTAVIRUS CORONAVIRUSCORONAVIRUS

COMMONALITY CONTINUEDCOMMONALITY CONTINUEDHUMAN PATHOGEN OR DISEASE (CONT.)HUMAN PATHOGEN OR DISEASE (CONT.) BOVINE PATHOGEN (CONT.)BOVINE PATHOGEN (CONT.)

VIRUSES (CONT.)VIRUSES (CONT.) VIRUSES (CONT.)VIRUSES (CONT.)

CYTOMEGALOVIRUSCYTOMEGALOVIRUS COMMONCOMMON BOVINE CMV AND IBRBOVINE CMV AND IBRHERPES INFECTIONSHERPES INFECTIONS COMMONCOMMON INFECTIOUS BOVINE INFECTIOUS BOVINE

RHINOTRACHEITIS RHINOTRACHEITISHIV (RETROVIRUS)HIV (RETROVIRUS) COMMONCOMMON BOVINE IMMUNE DEFICIENCY BOVINE IMMUNE DEFICIENCY

VIRUSVIRUS LENTIVIRUS (LOW LENTIVIRUS (LOW

PREVALENCE)PREVALENCE)VENEZUELEAN EQUINE ENCEPHALITISVENEZUELEAN EQUINE ENCEPHALITIS RARERARE BOVINE VEEBOVINE VEELYMPHOSARCOMALYMPHOSARCOMA RARERARE BOVINE ONCOVIRUS BOVINE ONCOVIRUS

LYMPHOSARC.LYMPHOSARC.PSUEDOCOWPOXPSUEDOCOWPOX RARERARE BOVINE PARAPOXVIRUSBOVINE PARAPOXVIRUSRHINOVIRUS (COMMON COLD)RHINOVIRUS (COMMON COLD) VERY COMMONVERY COMMON BOVINE RHINOVIRUSBOVINE RHINOVIRUS

YEAST, FUNGI, PROTOZOA, OTHER MICROBESYEAST, FUNGI, PROTOZOA, OTHER MICROBES

ASPERGILLOSISASPERGILLOSIS RARERARE ASPERGILLUS EXPOSURE COMMONASPERGILLUS EXPOSURE COMMONCANDIDIASISCANDIDIASIS COMMONCOMMON CANDIDA EXPOSURE COMMONCANDIDA EXPOSURE COMMONCYCLOSPORACYCLOSPORA RARERARE ABORTIONS?ABORTIONS?CRYPTOSPORIDIOSISCRYPTOSPORIDIOSIS VERY COMMONVERY COMMON CALF DIARRHEA, CALF DIARRHEA, C. PARVUMC. PARVUMGIARDIASISGIARDIASIS COMMONCOMMON CALF DIARRHEA, CALF DIARRHEA, G. LAMBLIA G. LAMBLIA CHLAMYDIOSESCHLAMYDIOSES COMMONCOMMON CHLAMYDIAL ABORTIONCHLAMYDIAL ABORTIONMYCOPLASMA PNEUMONIA, ARTHRITISMYCOPLASMA PNEUMONIA, ARTHRITIS COMMONCOMMON BOVINE MYCOPLASMAL PNEUMONIABOVINE MYCOPLASMAL PNEUMONIA

*APPLIED LIFE SCIENCES, R.H. BENNETT, PH.D., PRESIDENT, 8300 STARR ROAD, WINDSOR, CA 95492*APPLIED LIFE SCIENCES, R.H. BENNETT, PH.D., PRESIDENT, 8300 STARR ROAD, WINDSOR, CA 95492

The Future of Medicine

Will focus on the Immune System

Lets talk about heart disease

“A new test could save the lives of millions who don’t even know

they’re in danger” – US News & World Report

TRADITIONAL RISK FACTORS that can’t be changed:

1. Heredity

2. Gender

3. Increasing Age

TRADITIONAL RISK FACTORS that can be changed:

1. Smoking2. Cholesterol3. Hypertension4. Physical Inactivity5. Obesity6. Stress7. Substance Abuse

IMPORTANT NEWLY RECOGNIZED risk factors:

1. Homocysteine Levels

2. C-Reactive Protein Levels

Homocysteine: A Cardiovascular Risk Factor

Worth Considering

American Heart Disease Statistics

Heart Attacks• One heart attack in the US every

20 seconds

• 1.5 million heart attacks per year

• 500,000 deaths per year

• 250,000 occur within one hour

Strokes• 600,000 per year

• 160,000 deaths per year

• A stroke every 53 seconds

• 1 death every 3.3 minutes

• 4.5 million stroke survivors today

LAPD 4 year period death rate comparison

• Heart Disease—160

• Gun shots—5

Medical Science’s Solution to Heart Disease

Drugs Surgery

Why does incidence remain the same?

Cross-section of normal coronary artery

Old theory of cholesterol plaque formation

Severe atherosclerosis with narrowing plaque formation, and hemorrhage

Effects of Elevated Homocysteine

1) Damages inside lining of artery.

2) Damage causes increased permeability (leakage).

3) Germs and Bad Cholesterol (LDL) leak into arterial wall.

4) Homocysteine oxidizes LDL Cholesterol.

5) Oxidized LDL Cholesterol more dangerous form.

6) Germ-seeking Macrophages enter arterial wall.

7) Macrophages get diverted. Start ingesting “tasty” oxidized LDL Cholesterol.

8) Macrophages fill themselves with LDL Cholesterol. Look like they are filled with foam.

9) These “foam cells” are what constitute plaques.

10) Plaques cause ATHEROSCLEROSIS.

Effects of Elevated Homocysteine

While commercial labs state that “normal” homocysteine levels can range from 5 to 15 umol/L, a study published in

Circulation Nov. 15th, 1995 indicated that each 3 unit increase in homocysteine equals a 35% increase in cardiac risk.

“All the patients were tested for antibodies – a sign of past infection – to several bacteria and viruses, including herpes simplex virus 1 and 2, cytomegalovirus, Epstein-Barr virus, Haemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae and Helicobacter pylori.”

C-Reactive ProteinC-Reactive Protein is a protein in the body

whose level increases when there is inflammation. A study published in the New England Journal of Medicine involving 1086 apparently healthy men over an eight year period showed that those men with the highest level of C-Reactive Protein had a three-fold increase in the risk of heart attack and a two-fold increase in the risk of stroke.

Cardiovascular Evaluation

• Homocysteine

• Lipid profile (cholesterol)

• C-Reactive Protein (CRP)

Homocysteine

• Folic Acid

• B6

• B12

Cholesterol• Red rice yeast

– Significantly reduces:• Total Cholesterol• LDL (Bad) Cholesterol• Triglycerides

-Am J Clin Nutr 1999

• Garlic

Inflammation (CRP)

• Targeted Transfer Factor

• Red Rice Yeast

• Antioxidants

™

Block Oxidative DamageSelenium, Copper/Zinc, ResveratrolBeta carotene, Vitamin C, Vitamin E

Balances Normal Blood Pressure RangesCopper, Magnesium

Improve Toxin ClearanceFolic Acid, Vitamins B6 & B12, and Niacin

Increase the Pumping Efficiency of the HeartMagnesium, CoQ10

Relax the Blood VesselsArginine, Mg, Ginkgo biloba, Hawthorne,

Butcher’s Broom

TF Cardio™ The Most Effective Cardiovascular Supplement Ever!

French Paradox Lower incidence of Heart Disease

• Powerful Antioxidant

• Reduces Blood Clotting

• Increases HDL cholesterol (good cholesterol)

Bhat KPL, Kosmeder JW, 2nd. Antioxid Redox Signal 2001; 2(6): 1041-64.

ResveratrolResveratrol

SUMMARY of the Problem

• Heart Disease is the #1 Killer• Heart Disease is NOT a Simple

Plumbing Problem• The Immune System is Critically

Involved in Heart Disease• Infection may Initiate Heart Disease • Increased Homocysteine Levels add risk• Elevated C-Reactive Protein Levels add

risk

SUMMARY of a Solution• Immune System “Targeting” to Fight

Germs “Suppress” (Control) Inflammation

• Help the Blood Vessels Relax• Protect the Heart and Arteries from

Toxin and Oxidative Damage• Increase the Pumping Efficiency

of the Heart• Decrease Homocysteine levels• Decrease Cholesterol levels• Decrease C-Reactive Protein levels

Health Supplement Timeline

1970’s

1980’s

1990’s

2000’s

Multivitamins

Herbs

Antioxidants

Immune Support

“The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who knows the great enthusiasms, the great devotions, and spends himself in a worthy cause; who at best, if he wins, knows the thrills of high achievement, and, if he fails, at least fails daring greatly, so that his place shall never be with those cold and timid souls who know neither victory nor defeat.”

–Theodore Roosevelt

transfer factor

Health & Medicine

Transcript of transfer factor